Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08‐20

Conclusion.At tolerable doses, the combination of sorafenib and capecitabine seems an active and safe palliative treatment for HCC in class A and B‐7 patients with cirrhosis. The small sample size does not allow comparison with single‐agent sorafenib.

Source: The Oncologist - October 10, 2017 Category: Cancer & Oncology Authors: Yehuda Patt, Cristhiam Roȷas-Hernandez, Houman Mohammad Fekrazad, Pranshu Bansal, Fa Chyi Lee Tags: Hepatobiliary, Chinese Edition, Clinical Trial Results Source Type: research